New CBO brings more than 25 years of pharmaceutical business development experience

SOUTH RIDING, VA. – October 20, 2022Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and healthcare companies, has announced the placement of Patrick Genestin as Chief Business Officer at 1910 Genetics, a biotechnology company integrating artificial intelligence (AI), computation, and biological automation to accelerate the design of small molecule and protein therapeutics.

Genestin brings more than 25 years of pharmaceutical business development experience in leading collaborations ranging from licensing, co-development, and co-commercialization to mergers and acquisitions. Before joining 1910 Genetics, Genestin served as Vice President of Business Development and Pipeline Strategy at Hikma Pharmaceuticals and a member of the Specialty & Generics leadership team. In addition, he held the role of Vice President, Business Development & Licensing, at Sandoz, a Novartis company, and a member of the Sandoz North America Executive Committee. Genestin has also held various finance roles of increasing responsibilities at CSL Behring and Sanofi.

“Patrick Genestin is an extremely accomplished, passionate, and respected business leader with a penchant for establishing strategic partnerships, attracting new investment, and stimulating growth,” said Slone Partners CEO Leslie Loveless. “He brings solid experience across financial, portfolio, and business development operations and is well prepared to help advance 1910 Genetics through key collaborations & partnerships.”

“Patrick’s extensive experience working with industry leaders and creating value-added deals for companies makes him an invaluable addition to the 1910 Genetics executive team,” said Jen Nwankwo, Ph.D., 1910 Genetics’ Founder and Chief Executive Officer. “He has a long and successful track record of engineering multimillion-dollar collaborations between small and large multinational pharmaceutical companies, and we are proud that he has joined our team.”

A native of France, Genestin received his bachelor’s degree from Audencia (École Supérieure de Commerce) and holds a master’s of business administration (MBA) from Penn State University.

Slone Partners delivers the leaders who build amazing and diverse life sciences and healthcare organizations – People Are Our Science®. Founded in 2000, Slone Partners specializes in delivering world-class C-suite leadership, executive, and upper management talent to the most promising and established biotech, diagnostics, research tools, healthcare, precision medicine, medical device, and laboratory services companies. With national and global clients, Slone Partners uniquely and precisely provides an array of executive search and advisory services, including diversity, equity, and inclusion strategy, to innovative life sciences and healthcare companies. To learn more about Slone Partners’ value proposition and processes, visit or call 888.784.3422.

1910 Genetics integrates AI, computation, and biological automation to accelerate the design of small molecule and protein therapeutics. The company blends AI-driven drug design with biological wet-lab automation to increase productivity and decrease failure rates across the pharmaceutical R&D process. Using its multi-platform drug discovery engines – ELVIS™ and ROSALYND™ – 1910 Genetics can generate more novel drug candidates, shorten the timeline, cut operational costs, and increase the probability of success compared to traditional pharmaceutical methods. 1910 Genetics’ therapeutic area-agnostic, end-to-end technology powers the full length of early drug discovery – from novel hit discovery to hit to lead and lead optimization. 1910 Genetics is currently applying its technology to drug discovery programs in several areas, including, but not limited to, neuroscience, oncology, immunology, and infectious diseases. The company was founded in 2018 and is headquartered in Boston, Massachusetts. To learn more about 1910 Genetics, visit